Millennium: The Takeda Oncology Company Joins the WIN Consortium in Personalized Cancer Medicine
Posted: Friday, March 29, 2013
Millennium: The Takeda Oncology Company and the WIN Consortium Become Partners in the Fight Against Cancer
Cambridge, MA., March 29, 2013 — Millennium: The Takeda Oncology Company and the Worldwide Innovative Network (WIN) in personalized cancer medicine Consortium today announced the formation of a new partnership focused on bringing the latest advances in personalized cancer treatments to patients. The WIN Consortium is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide. It was founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone.
“Millennium has a long-standing commitment to advancing personalized medicine in oncology,” said Jesus Gomez Navarro, M.D., Vice President, Clinical Research at Millennium and delegate to the WIN Consortium. “WIN’s global network of cancer centers and industry partners provides Millennium with unique opportunities to build successful industry-leading partnerships that accelerate the development of new therapies and advance our aspiration to cure cancer.”
“WIN’s achievements are built by the collaborative efforts of its members,” said John Mendelsohn, M.D., Director, Khalifa Institute for Personalized Cancer Therapy and Past-President, The University of Texas MD Anderson Cancer Center, and Chairman of the WIN Consortium. “Millennium’s focus on partnership development and the development of novel oncology therapeutics for a global population strongly align with WIN’s mission and goals. This partnership increases the potential of the Consortium and will enhance its future achievements. We are thrilled that Millennium has become a premier member of WIN.”
About Millennium
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.
About the WIN Consortium
Initiated in 2010 by the University of Texas MD Anderson Cancer Center (USA) and the Institut Gustave Roussy (France), the WIN Consortium is a global network of 28 leading organizations from the academic, pharmaceutical, biotechnology, healthcare IT, and patient advocacy sectors working to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN is a non-governmental, not-for-profit organization headquartered in Paris.
Contacts
Millennium: Manisha Pai
Manisha.pai@mpi.com
WIN: Catherine Bresson
Catherine.bresson@winconsortium.org